Testing a new targeted treatment for solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Skin clinical trials.
This trial tests an experimental drug that targets tumors with a special protein detected by a PET scan. It may help treat certain cancers like breast, head and neck, pancreatic, or brain cancers that have grown despite prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with breast, head and neck, pancreatic, or brain cancer that has spread or grown recently.
- You are expected to live at least 3 more months.
- You are generally able to care for yourself (ECOG score 0-2).
- You have a tumor that shows high uptake on a special PET scan (a way to see the tumor).
- You have recovered from side effects of prior cancer treatments.
- You are not pregnant or breastfeeding and agree to use effective birth control.
- You have not had cancer treatment (chemo, radiation, immunotherapy) or an investigational drug within the last 4 weeks.
- You do not have other cancers, serious heart conditions, or uncontrolled infections.
- Your blood counts, liver, and kidney function are within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
This trial uses a new radioactive tracer that attaches to a protein found on many solid tumors, allowing doctors to see tumors on a PET scan. It may help improve how tumors are detected and monitored.
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.